A comparison of progestins within three classes: Differential effects on learning and memory in the aging surgically menopausal rat

Brittany Braden, Madeline G. Andrews, Jazmin I. Acosta, Sarah E. Mennenga, Courtney Lavery, Heather Bimonte-Nelson

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Introduction: For decades, progestins have been included in hormone therapies (HT) prescribed to women to offset the risk of unopposed estrogen-induced endometrial hyperplasia. However, the potential effects on cognition of subcategories of clinically used progestins have been largely unexplored. Methods: In two studies, the present investigation evaluated the cognitive effects of norethindrone acetate (NETA), levonorgestrel (LEVO), and medroxyprogesterone acetate (MPA) on the water radial-arm maze (WRAM) and Morris water maze (MM) in middle-aged ovariectomized rats. Results: In Study 1, six-weeks of a high-dose NETA treatment impaired learning and delayed retention on the WRAM, and impaired reference memory on the MM. Low-dose NETA treatment impaired delayed retention on the WRAM. In Study 2, high-dose NETA treatment was reduced to four-weeks and compared to MPA and LEVO. As previously shown, MPA impaired working memory performance during the lattermost portion of testing, at the highest working memory load, impaired delayed retention on the WRAM, and impaired reference memory on the MM. NETA also impaired performance on these WRAM and MM measures. Interestingly, LEVO did not impair performance, but instead enhanced learning on the WRAM. Conclusions: The current study corroborates previous evidence that the most commonly prescribed FDA-approved progestin for HT, MPA, impairs learning and memory in the ovariectomized middle-aged rat. When progestins from two different additional subcategories were investigated, NETA impaired learning and memory similarly to MPA, but LEVO enhanced learning. Future research is warranted to determine LEVO's potential as an ideal progestin for optimal health in women, including for cognition.

Original languageEnglish (US)
JournalBehavioural Brain Research
DOIs
StateAccepted/In press - Apr 14 2016

Fingerprint

Progestins
Learning
Medroxyprogesterone Acetate
Water
Levonorgestrel
Short-Term Memory
Cognition
Hormones
Endometrial Hyperplasia
Therapeutics
Women's Health
norethindrone acetate
Estrogens

Keywords

  • Aging
  • Cognition
  • Hormone therapy
  • Memory
  • Menopause
  • Progestin

ASJC Scopus subject areas

  • Behavioral Neuroscience

Cite this

A comparison of progestins within three classes : Differential effects on learning and memory in the aging surgically menopausal rat. / Braden, Brittany; Andrews, Madeline G.; Acosta, Jazmin I.; Mennenga, Sarah E.; Lavery, Courtney; Bimonte-Nelson, Heather.

In: Behavioural Brain Research, 14.04.2016.

Research output: Contribution to journalArticle

@article{49640786605146718fe2a31f8afe43fa,
title = "A comparison of progestins within three classes: Differential effects on learning and memory in the aging surgically menopausal rat",
abstract = "Introduction: For decades, progestins have been included in hormone therapies (HT) prescribed to women to offset the risk of unopposed estrogen-induced endometrial hyperplasia. However, the potential effects on cognition of subcategories of clinically used progestins have been largely unexplored. Methods: In two studies, the present investigation evaluated the cognitive effects of norethindrone acetate (NETA), levonorgestrel (LEVO), and medroxyprogesterone acetate (MPA) on the water radial-arm maze (WRAM) and Morris water maze (MM) in middle-aged ovariectomized rats. Results: In Study 1, six-weeks of a high-dose NETA treatment impaired learning and delayed retention on the WRAM, and impaired reference memory on the MM. Low-dose NETA treatment impaired delayed retention on the WRAM. In Study 2, high-dose NETA treatment was reduced to four-weeks and compared to MPA and LEVO. As previously shown, MPA impaired working memory performance during the lattermost portion of testing, at the highest working memory load, impaired delayed retention on the WRAM, and impaired reference memory on the MM. NETA also impaired performance on these WRAM and MM measures. Interestingly, LEVO did not impair performance, but instead enhanced learning on the WRAM. Conclusions: The current study corroborates previous evidence that the most commonly prescribed FDA-approved progestin for HT, MPA, impairs learning and memory in the ovariectomized middle-aged rat. When progestins from two different additional subcategories were investigated, NETA impaired learning and memory similarly to MPA, but LEVO enhanced learning. Future research is warranted to determine LEVO's potential as an ideal progestin for optimal health in women, including for cognition.",
keywords = "Aging, Cognition, Hormone therapy, Memory, Menopause, Progestin",
author = "Brittany Braden and Andrews, {Madeline G.} and Acosta, {Jazmin I.} and Mennenga, {Sarah E.} and Courtney Lavery and Heather Bimonte-Nelson",
year = "2016",
month = "4",
day = "14",
doi = "10.1016/j.bbr.2016.06.053",
language = "English (US)",
journal = "Behavioural Brain Research",
issn = "0166-4328",
publisher = "Elsevier",

}

TY - JOUR

T1 - A comparison of progestins within three classes

T2 - Differential effects on learning and memory in the aging surgically menopausal rat

AU - Braden, Brittany

AU - Andrews, Madeline G.

AU - Acosta, Jazmin I.

AU - Mennenga, Sarah E.

AU - Lavery, Courtney

AU - Bimonte-Nelson, Heather

PY - 2016/4/14

Y1 - 2016/4/14

N2 - Introduction: For decades, progestins have been included in hormone therapies (HT) prescribed to women to offset the risk of unopposed estrogen-induced endometrial hyperplasia. However, the potential effects on cognition of subcategories of clinically used progestins have been largely unexplored. Methods: In two studies, the present investigation evaluated the cognitive effects of norethindrone acetate (NETA), levonorgestrel (LEVO), and medroxyprogesterone acetate (MPA) on the water radial-arm maze (WRAM) and Morris water maze (MM) in middle-aged ovariectomized rats. Results: In Study 1, six-weeks of a high-dose NETA treatment impaired learning and delayed retention on the WRAM, and impaired reference memory on the MM. Low-dose NETA treatment impaired delayed retention on the WRAM. In Study 2, high-dose NETA treatment was reduced to four-weeks and compared to MPA and LEVO. As previously shown, MPA impaired working memory performance during the lattermost portion of testing, at the highest working memory load, impaired delayed retention on the WRAM, and impaired reference memory on the MM. NETA also impaired performance on these WRAM and MM measures. Interestingly, LEVO did not impair performance, but instead enhanced learning on the WRAM. Conclusions: The current study corroborates previous evidence that the most commonly prescribed FDA-approved progestin for HT, MPA, impairs learning and memory in the ovariectomized middle-aged rat. When progestins from two different additional subcategories were investigated, NETA impaired learning and memory similarly to MPA, but LEVO enhanced learning. Future research is warranted to determine LEVO's potential as an ideal progestin for optimal health in women, including for cognition.

AB - Introduction: For decades, progestins have been included in hormone therapies (HT) prescribed to women to offset the risk of unopposed estrogen-induced endometrial hyperplasia. However, the potential effects on cognition of subcategories of clinically used progestins have been largely unexplored. Methods: In two studies, the present investigation evaluated the cognitive effects of norethindrone acetate (NETA), levonorgestrel (LEVO), and medroxyprogesterone acetate (MPA) on the water radial-arm maze (WRAM) and Morris water maze (MM) in middle-aged ovariectomized rats. Results: In Study 1, six-weeks of a high-dose NETA treatment impaired learning and delayed retention on the WRAM, and impaired reference memory on the MM. Low-dose NETA treatment impaired delayed retention on the WRAM. In Study 2, high-dose NETA treatment was reduced to four-weeks and compared to MPA and LEVO. As previously shown, MPA impaired working memory performance during the lattermost portion of testing, at the highest working memory load, impaired delayed retention on the WRAM, and impaired reference memory on the MM. NETA also impaired performance on these WRAM and MM measures. Interestingly, LEVO did not impair performance, but instead enhanced learning on the WRAM. Conclusions: The current study corroborates previous evidence that the most commonly prescribed FDA-approved progestin for HT, MPA, impairs learning and memory in the ovariectomized middle-aged rat. When progestins from two different additional subcategories were investigated, NETA impaired learning and memory similarly to MPA, but LEVO enhanced learning. Future research is warranted to determine LEVO's potential as an ideal progestin for optimal health in women, including for cognition.

KW - Aging

KW - Cognition

KW - Hormone therapy

KW - Memory

KW - Menopause

KW - Progestin

UR - http://www.scopus.com/inward/record.url?scp=84978897984&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84978897984&partnerID=8YFLogxK

U2 - 10.1016/j.bbr.2016.06.053

DO - 10.1016/j.bbr.2016.06.053

M3 - Article

C2 - 27368418

AN - SCOPUS:84978897984

JO - Behavioural Brain Research

JF - Behavioural Brain Research

SN - 0166-4328

ER -